GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT07073053

Not yet recruitingPhase 4

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

Lead sponsor

Taipei Veterans General Hospital, Taiwan

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Cardiovascular disease, Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•CGM time-in-range•HbA1c, change•Flow-Mediated Dilatation (FMD)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07073053

Org study ID2025-02-004C

Timeline

Milestones

Study first posted2025-07-18actual

Last update posted2025-07-18actual

Study start2025-10-01estimated

Primary completion2028-07-31estimated

Study completion2028-07-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Cardiovascular diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. adults (>=20 years old),

2. Type 2 Diabetes with coronary arterial disease underwent angioplasty within 3 months with SGLT2 inhibitors -

Exclusion criteria

1. age<20 years old,

2. pregnant women,

3. eGFR<30 ml/min/1.73m2,

4. received GLP-1 agonist in the recent 3 months -

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

Cardiometabolic biomarkers

Safety / tolerability / PK

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint

change of Time-in-range (%)

Time frame:From enrollment to the end of treatment at 24 weeks

CGM time-in-range

change from baseline, improvement

Primary/protocol endpoint

change of HbA1c

Time frame:From enrollment to the end of treatment at 24 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

change of fasting glucose

Time frame:From enrollment to the end of treatment at week 24

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

3 endpoints

Primary/protocol endpoint

change of Flow-Mediated Dilatation (FMD)

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Secondary/protocol endpoint

change of Peripheral Arterial Tonometry (PAT)

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Other/protocol endpoint

change of urinary 8-iso PGF 2alfa

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Hypoglycemic episodes

Time frame:from enrollment to the end of treatment at week 24.

Documented hypoglycemia

event count, event

Other (unclassified)

5 endpoints

Secondary/protocol endpoint/low confidence

change of serum ROS measurements

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Other/protocol endpoint/low confidence

change of serum IL-1β

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, descriptive

Other/protocol endpoint

change of serum IL-6

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Other/protocol endpoint/low confidence

change of serum IL-10

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Other/protocol endpoint/low confidence

change of serum TNF-α

Time frame:From enrollment to the end of treatment at 24 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.